AstraZeneca plc (AZN) Rating Reiterated by Citigroup Inc.
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reiterated by Citigroup Inc. in a research report issued to clients and investors on Wednesday. They currently have a GBX 6,000 ($78.32) target price on the biopharmaceutical company’s stock. Citigroup Inc.’s price objective points to a potential upside of 19.40% from the company’s current price.
Several other analysts have also recently issued reports on AZN. Deutsche Bank AG reissued a “buy” rating on shares of AstraZeneca plc in a research note on Tuesday, June 7th. JPMorgan Chase & Co. set a GBX 3,900 ($50.91) price objective on shares of AstraZeneca plc and gave the company a “neutral” rating in a research note on Tuesday, June 7th. Berenberg Bank reissued a “buy” rating and set a GBX 4,950 ($64.61) price objective on shares of AstraZeneca plc in a research note on Thursday, June 9th. Jefferies Group boosted their price objective on shares of AstraZeneca plc from GBX 3,900 ($50.91) to GBX 4,100 ($53.52) and gave the company a “hold” rating in a research note on Tuesday, June 14th. Finally, Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a research note on Tuesday, June 14th. Five research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) opened at 4996.8931 on Wednesday. The company has a 50-day moving average price of GBX 5,009.44 and a 200-day moving average price of GBX 4,418.92. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The firm’s market capitalization is GBX 63.21 billion.
The company also recently disclosed a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were paid a dividend of GBX 68.70 ($0.90) per share. This represents a yield of 1.37%. The ex-dividend date was Thursday, August 11th.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.